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a b s t r a c t
Excessive ethanol ingestion causes gastric mucosal damage through the inﬂammatory and oxidative
processes. The present study was aimed to evaluate the protective effect of thalidomide on ethanol-
induced gastric mucosal damage in mice. The animals were pretreated with vehicle or thalidomide (30
or 60 mg/kg, orally), and one hour later, the gastric mucosal injury was induced by oral administration
of acidiﬁed ethanol. The animals were euthanized one hour after ethanol ingestion, and gastric tissues
were collected to biochemical analyzes. The gastric mucosal lesions were assessed by macroscopic and
histopathological examinations. The results showed that treatment of mice with thalidomide prior to
the administration of ethanol dose-dependently reduced the gastric ulcer index. Thalidomide pretreat-
ment signiﬁcantly reduced the levels of pro-inﬂammatory cytokines [tumor necrosis factor (TNF)-a,
interleukin (IL)-1b, IL-6], malondialdehyde (MDA) and myeloperoxidase (MPO) activity. In addition,
thalidomide signiﬁcantly inhibited ethanol-induced nitric oxide (NO) overproduction in gastric tissue.
Histological observations showed that ethanol-induced gastric mucosal damage was attenuated by
thalidomide pretreatment. It seems that thalidomide as an anti-inﬂammatory agent may have a protec-
tive effect against alcohol-induced mucosal damage by inhibition of neutrophil inﬁltration and reducing
the production of nitric oxide and inﬂammatory cytokines in gastric tissue.
 2014 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Peptic ulcer disease is a common gastrointestinal disorder and
is an important health problem in worldwide. The pathophysiology
of gastric mucosal injury results from an imbalance between pro-
tective factors and aggressive factors. Various damaging agents
are involved in the pathogenesis of gastric mucosal injury, includ-
ing alcohol intake, gastric hydrochloric acid, free oxygen radicals,
non-steroidal anti-inﬂammatory drugs (NSAIDs), stress, and Heli-
cobacter pylori infection [1,2]. It is well known that ethanol causes
acute gastric mucosal injuries through different mechanisms,
including gastric microcirculatory disturbances, disruption of the
gastric mucosal barrier and gastric epithelial cell damage [3,4].
Alcohol can trigger some of the acute inﬂammatory pathways lead-
ing to gastric mucosal injury [5]. It has been shown that neutrophil
inﬁltration into the gastric mucosa has a critical role in the devel-
opment of gastric mucosal inﬂammation and damage. Inﬁltration
of neutrophils and mononuclear cells into the gastric mucosa
during inﬂammation stimulates the synthesis and release of sev-
eral pro-inﬂammatory mediators. It has been shown that some
pro-inﬂammatory cytokines such as TNF-a, IL-1b, IL-6, IL-8 and
IL-10 are involved in the pathogenesis of alcohol mediated mucosal
injury [6–9]. NO plays an important role in regulating physiological
functions of gastrointestinal tract, however, NO has been impli-
cated as a contributor to tissue injury in the gastrointestinal tract
during inﬂammatory responses. Thus, NO appears to have a dual
role in the inﬂammatory processes [10,11].
A number of compounds with anti-inﬂammatory activity have
been studied to prevent the gastric mucosal injury induced by
ethanol in animal models [7–9]. Thalidomide (a-N-phthalimido
glutarimide) as an anti-inﬂammatory agent is effective in the treat-
ment of inﬂammatory disorders. Thalidomide is a glutamic acid
derivative that was ﬁrst introduced in 1956 as a sedative drug
but was withdrawn from clinical use in 1962 due to its teratogenic
effects. Thalidomide is now used as a treatment for cutaneous
lesions associated with erythema nodosum leprosum (ENL) and
multiple myeloma. Thalidomide causes some adverse effects, par-
ticularly teratogenicity and peripheral neuropathy. New structural
analogues of thalidomide have been developed in order to improve
therapeutic efﬁcacy and reducing side effects [12]. Several studies
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